| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,625,000 |
| Market
Cap: |
159.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.59 - $8.3 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Coherus BioSciences is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Co. in-licensed its lead immuno-oncology product candidate, toripalimab (CHS-007), an anti-PD-1 antibody, from Shanghai Junshi Biosciences Co., Ltd. Toripalimab is being evaluated in late-stage clinical trials for the treatment of a range of tumor types. Co.'s commercial portfolio includes two U.S. Food and Drug Administration-approved biologics, including UDENYCA® (pegfilgrastim-cbqv), a biosimilar to Neulasta®, a granulocyte-colony stimulating factor and YUSIMRY™ (adalimumab-aqvh), its Humira® (adalimumab) biosimilar product.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
223,100 |
223,100 |
223,100 |
| Total Sell Value |
$0 |
$449,770 |
$449,770 |
$449,770 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reider Paul |
Chief Commercial Officer |
• – – |
2023-03-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
89,504 |
|
-23% |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
86,250 |
654,853 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
131,323 |
|
- |
|
| Mcmichael Bryan J |
See Remarks |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
26,386 |
|
- |
|
| Stilwell Mcdavid |
Chief Financial Officer |
• – – |
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
104,243 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2023-01-11 |
4 |
D |
$10.26 |
$36,957 |
D/D |
(3,602) |
91,323 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2023-01-10 |
4 |
D |
$9.85 |
$35,480 |
D/D |
(3,602) |
94,925 |
|
- |
|
| Mcmichael Bryan J |
See Remarks |
• – – |
2023-01-07 |
4 |
D |
$9.58 |
$16,276 |
D/D |
(1,699) |
13,886 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2022-12-30 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,000 |
432,684 |
|
- |
|
| Mcmichael Bryan J |
See RemarksOfficer |
• – – |
2022-09-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,584 |
|
-19% |
|
| Stilwell Mcdavid |
Chief Financial Officer |
• – – |
2022-04-01 |
4 |
D |
$12.85 |
$44,435 |
D/D |
(3,458) |
69,680 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2022-04-01 |
4 |
D |
$12.85 |
$44,435 |
D/D |
(3,458) |
103,963 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2022-02-28 |
4 |
A |
$2.08 |
$62,501 |
D/D |
29,994 |
40,000 |
|
- |
|
| Wahlstrom Mats |
Director |
– • – |
2022-02-25 |
4 |
A |
$11.64 |
$116,433 |
D/D |
10,006 |
10,006 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2022-01-11 |
4 |
D |
$14.36 |
$51,452 |
D/D |
(3,583) |
107,421 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2022-01-10 |
4 |
D |
$14.30 |
$59,345 |
D/D |
(4,150) |
111,004 |
|
- |
|
| Vexler Vladimir |
Chief Scientific Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
115,154 |
|
- |
|
| Lanfear Dennis M |
President & CEO |
• • – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
86,250 |
579,508 |
|
- |
|
| Stilwell Mcdavid |
Chief Financial Officer |
• – – |
2022-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
73,138 |
|
- |
|
| Stilwell Mcdavid |
Chief Financial Officer |
• – – |
2021-10-15 |
4 |
S |
$16.80 |
$58,919 |
D/D |
(3,507) |
31,611 |
|
31% |
|
| Healy James |
Director |
– • – |
2021-09-29 |
4 |
S |
$16.12 |
$4,611,545 |
I/I |
(286,076) |
0 |
|
24% |
|
| Healy James |
Director |
– • – |
2021-09-28 |
4 |
S |
$17.17 |
$829,809 |
I/I |
(48,329) |
286,076 |
|
27% |
|
| Healy James |
Director |
– • – |
2021-09-27 |
4 |
S |
$18.06 |
$1,808,709 |
I/I |
(100,150) |
334,405 |
|
34% |
|
| Anicetti Vincent R |
Chief Operating Officer |
• – – |
2021-07-06 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
124,790 |
|
- |
|
| Stilwell Mcdavid |
Chief Financial Officer |
• – – |
2021-06-09 |
4 |
B |
$13.42 |
$49,668 |
D/D |
3,700 |
35,118 |
2.74 |
26% |
|
31 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.09 (4.46%) 
